PPT-MANAGING THE ARBITRATION PROCESS TO REDUCE COSTS WITHOUT SACRIFICING POSITIVE RESULTS

Edward Cassady Senior Vice President and Chief Financial Officer Robins amp Morton C Allen Gibson Jr Partner Womble Carlyle Sandridge amp Rice LLP Robyn Miller Senior Vice President and General Counsel. Jakob Ragnwaldh. Mannheimer. . Swartling. , Stockholm. 10 September 2010. Introduction. The topic: Can a State during the course of an arbitration obtain an order from a Tribunal securing its costs in the event that the State is ultimately successful in its . International arbitration report Norton Rose Fulbright – 2015 Amendments to the Arbitration and Conciliation Act 1996 (the Act) were �rst approved by the Union Cabinet in December 201 SAI Meeting. Presented . by: . Ogden CSD. Overview. Ogden’s Financial Picture. Decision Analysis Process. State the Decision. Establish and Classify Objectives. List Alternatives. Evaluate Alternatives. Will the new Arbitration law reduce delays and cost?. Pre-amendment scenario making Arbitration costly and long-drawn:. Ad-hoc arbitrations were left to the whims of the arbitrators;. Large number of sittings were there and arbitrations went on for years altogether;. Kamal Shah, . Partner and Head of Africa and India Groups, Stephenson Harwood LLP. Tunde Fagbohunlu, SAN, . Head of Dispute Resolution, Aluko & Oyebode. Law Digest Conference, 3 November 2016 . Introduction. Award and Assessment of Costs. Hong . Kong 2017 . Mary Thomson. . Chartered Arbitrator, Barrister, Mediator & Adjudicator. Vice Chair, CIArb EAB . . 1. Award . and Assessment of Costs. Introduction. eventsof. . nivolumab. and . docetaxel. in the . CheckMate. 017 and . CheckMate. 057 phase III NSCLC trials. . Kartik. . Venkatachalam. Intervista a Cesare . Gridelli. Background: Nivo, a PD-1 antibody, received FDA approval based on superior overall survival in metastatic squamous (SQ) and non-squamous (NSQ) NSCLC patients who have progressed on or after platinum-based doublet chemotherapy. The purpose of this study was to assess the frequency and associated costs of grade 2–4 AEs in the CheckMate 017 (SQ) and CheckMate 057 (NSQ) phase III pivotal trials of nivo vs doc in stage IIIB/IV NSCLC. Methods: Patient-level data from these two trials were utilized to estimate the frequency of TRAEs requiring management in the nivo and doc arms, including serious and non-serious TRAEs. Minimum follow-up for AE reporting at database lock was 12 months. Grade 3–4 AE costs by event were identified from Healthcare Cost and Utilization Project (HCUP) data in 2010, which were adjusted to reflect 2012-equivalent US costs. Healthcare utilization associated with grade 2 AEs was based on clinical opinion and costs were based on HCUP or other sources as appropriate. Results: In both trials, more TRAEs were observed with doc than with nivo (Table), and the cost of managing TRAEs was 15.8 and 10.7 times higher in the doc arm vs the nivo arm for the CheckMate 017 and CheckMate 057 trials, respectively. Patients in the doc arm incurred an additional $6,585 and $5,422 per patient in managing AEs compared with patients in the nivo arm in the above two trials, respectively. The total estimated costs of managing TRAEs during these trials are presented in the Table. Conclusions: Large estimated differences in costs were observed in managing TRAEs, favoring nivo in the CheckMate 017 and CheckMate 057 pivotal trials. The reduction in costs for managing AEs with the use of nivo should be considered when assessing the value of nivo in this patient population.. Fabrizio Arossa and . Edoardo . Marcenaro . Rome, 31 March 2016. Introduction. How is the decision on costs . disciplined?. Agreement of the . parties. Applicable law . Institutional . rules. Other rules. Some Thoughts and Suggestions. Trevor . Harrison. Maritime Arbitrator and Mediator. Bunkers: Qualifying Quality. IBIA . Forum. MLE, Liverpool. , . 18. th. June . 2014. Full Member. Panel Member. 2. Bunker disputes in outline. 8. th. Annual . Decommissioning & Abandonment Summit . Debbie . McIntosh, Head of Subsurface & Wells Practice . 25. th. February . 2016. This document has been prepared solely for . 8. th. Annual Decommissioning & . Focusing on Triglycerides. Primary and Secondary CVD Prevention Trials: . Evaluating Treatment of Triglycerides. Why Have Outcomes Trials of TG-Lowering Drugs Failed to Reach Primary Endpoints? . ASCEND . lufwanyama. neonatal survival study. Christopher J. Gill MD MS. Center for Global Health and Development. Department of International Health. Boston University School of Public Health. ICIUM 2012, Antalya Turkey. Managing and strategizing pre-disputes phase. Session presenters: . Christopher Lau, Senior Counsel, Barrister, 3 Verulam Buildings, London, MCIA Council Member. Promod. Nair, Founder, Arista Law Chambers, MCIA Council Member. Looking at areas of pain. What is pain?. Pacing. Managing pain. Text 003. Areas of pain . Hip Pain. The painful areas are usually the lower back, buttocks and groin. Some people also feel discomfort from the top of their thigh down to the knee....